NEW YORK, Jan. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 



